Drugs / ABBV-787
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06068868 | Nov 2023 → Feb 2025 | acute myeloid leukemia | AbbVie | Terminated | No outcome recorded Stop: Business |
| Phase not stated1 trial | ||||||
| — | NCT06439966 | — | acute myeloid leukemia | AbbVie | No longer available | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-787 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06439966 ↗ |
| Route | Intravenous | “Participants will receive intravenous (IV) infusions of ABBV-787” NCT06068868 ↗ |